VTRS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: PFE MRK BMY JNJ ABBV GSK LLY AMGN SNY NVS

| Held by: VTI VOO VB VBR RSP SPY IVV SPYD CALF XLV

Index	S&P 500	P/E	-	EPS (ttm)	-2.91	Insider Own	2.30%	Shs Outstand	1.17B	Perf Week	-8.40%
Market Cap	11.19B	Forward P/E	3.93	EPS next Y	2.44	Insider Trans	0.28%	Shs Float	1.14B	Perf Month	-10.20%
Enterprise Value	25.29B	PEG	-	EPS next Q	0.62	Inst Own	83.07%	Short Float	3.56%	Perf Quarter	7.62%
Income	-3468.30M	P/S	0.80	EPS this Y	-14.12%	Inst Trans	0.80%	Short Ratio	4.31	Perf Half Y	5.49%
Sales	14.06B	P/B	0.72	EPS next Y	7.26%	ROA	-8.28%	Short Interest	40.53M	Perf YTD	-22.89%
Book/sh	13.36	P/C	16.77	EPS next 5Y	0.35%	ROE	-19.77%	52W High	13.55 -29.15%	Perf Year	-15.34%
Cash/sh	0.57	P/FCF	6.39	EPS past 3/5Y	20.30% -	ROIC	-12.15%	52W Low	6.85 40.15%	Perf 3Y	-0.83%
Dividend Est.	0.48 (5.02%)	EV/EBITDA	6.42	Sales past 3/5Y	-6.26% 5.04%	Gross Margin	39.16%	Volatility	2.69% 2.08%	Perf 5Y	-38.60%
Dividend TTM	0.48 (5.00%)	EV/Sales	1.80	EPS Y/Y TTM	-438.39%	Oper. Margin	8.41%	ATR (14)	0.25	Perf 10Y	-80.02%
Dividend Ex-Date	Aug 22, 2025	Quick Ratio	0.68	Sales Y/Y TTM	-7.47%	Profit Margin	-24.67%	RSI (14)	34.62	Recom	2.82
Dividend Gr. 3/5Y	13.30% -	Current Ratio	1.28	EPS Q/Q	98.58%	SMA20	-7.90%	Beta	0.90	Target Price	11.17
Payout	-	Debt/Eq	0.95	Sales Q/Q	-5.42%	SMA50	-1.75%	Rel Volume	1.89	Prev Close	9.96
Employees	32000	LT Debt/Eq	0.83	Earnings	Aug 07 BMO	SMA200	-3.44%	Avg Volume	9.40M	Price	9.60
IPO	Mar 17, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.55% 3.32%	Trades		Volume	17,792,876	Change	-3.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-25	Initiated	Goldman	Neutral	$10
Jul-19-24	Resumed	Jefferies	Buy	$15
Oct-23-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $9
Jun-23-23	Downgrade	Barclays	Equal Weight → Underweight	$11
Apr-24-23	Downgrade	Barclays	Overweight → Equal Weight	$11
Feb-17-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$16 → $14
Jan-27-23	Upgrade	Jefferies	Hold → Buy	$13 → $15
Nov-10-22	Upgrade	UBS	Sell → Neutral	$9 → $12
Nov-08-22	Upgrade	Piper Sandler	Underweight → Neutral	$10
Oct-21-22	Resumed	Jefferies	Hold	$11
Jun-14-22	Initiated	UBS	Sell	$9
May-10-22	Downgrade	Piper Sandler	Neutral → Underweight	$10
Mar-01-22	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $13
Jun-15-21	Initiated	Citigroup	Neutral	$16
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$24
Mar-08-21	Downgrade	Goldman	Buy → Neutral	$20 → $15
Mar-02-21	Downgrade	JP Morgan	Overweight → Neutral	$21 → $18
Feb-26-21	Downgrade	Wolfe Research	Outperform → Peer Perform	$17
Jan-05-21	Initiated	Argus	Hold

Show Previous Ratings

Sep-04-25 03:45AM	Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris (Zacks)
Sep-03-25 11:30AM	Insider Watch: 3 CEOs Buying the Dip (Zacks)
Sep-02-25 12:57PM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
Aug-29-25 05:03AM	Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women's Health (Insider Monkey)
Aug-19-25 11:34PM	Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment (StockStory)
09:00AM	Loading…
09:00AM	Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer (PR Newswire)
Aug-14-25 01:34AM	5 Must-Read Analyst Questions From Viatris's Q2 Earnings Call (StockStory)
Aug-13-25 12:23AM	VTRS Q2 Deep Dive: Pipeline Progress and Cost Discipline Drive Results Amid Industry Headwinds (StockStory)
Aug-12-25 06:32AM	FDA gives approval to Viatris for Iron Sucrose Injection (Pharmaceutical Business Review)
Aug-11-25 12:31PM	Why Viatris (VTRS) Stock Is Up Today (StockStory)
09:29AM	Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. (PR Newswire)
Aug-08-25 01:10PM	EpiPen patent expiry opens new era for innovation (Pharmaceutical Technology)
Aug-07-25 05:43PM	Analyst Report: Viatris Inc. (Morningstar Research) +7.31%
02:39PM	Viatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars (StockStory)
11:00AM	Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates (Zacks)
09:30AM	Loading…
09:30AM	Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics (Zacks)
08:05AM	Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates (Zacks)
07:07AM	Viatris: Q2 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance (PR Newswire)
Aug-06-25 09:15AM	Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Aug-05-25 11:10PM	Viatris (VTRS) Reports Earnings Tomorrow: What To Expect (StockStory)
08:37AM	Viatris Stock: Analyst Estimates & Ratings (Barchart)
06:59AM	Viatris Announces Quarterly Dividend (PR Newswire)
06:55AM	Viatris Announces Appointment of David Simmons to the Company's Board of Directors (PR Newswire)
12:30AM	[Latest] Global Paracetamol Market Size/Share Worth USD 1460.23 Million by 2034 at a 5.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-04-25 02:07PM	Viatris Poised to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Aug-01-25 10:00AM	Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference (PR Newswire)
Jul-31-25 05:27AM	Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health (GlobeNewswire)
Jul-30-25 04:30AM	[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Jul-25-25 03:00AM	GM Is Loading Up on Its Own Shares. Investors Should Follow Suit. (Barrons.com)
07:38AM	Loading…
Jul-24-25 07:38AM	Novo Nordisk defeated in Wegovy patent dispute by Viatris (Pharmaceutical Technology)
Jul-23-25 07:42AM	What to Expect From Viatris' Next Quarterly Earnings Report (Barchart)
Jul-21-25 09:48AM	VTRS Down on Late-Stage Study Failure of Eye Disease Drug (Zacks)
07:12AM	Viatris blepharitis ointment fails Phase III trial (Clinical Trials Arena)
Jul-18-25 05:01PM	Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target (GuruFocus.com)
02:41PM	Analyst Report: Viatris Inc. (Morningstar Research)
12:25PM	Why Viatris (VTRS) Stock Is Falling Today (StockStory)
08:47AM	Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target (Barrons.com)
06:59AM	Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis (PR Newswire)
Jul-17-25 02:46AM	Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 (Insider Monkey)
Jul-16-25 11:35PM	Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
Jul-15-25 08:59AM	Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma (Insider Monkey)
06:59AM	Viatris Certified as a Great Place to Work® in Canada (PR Newswire)
Jul-11-25 11:27AM	Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT (Insider Monkey)
Jun-27-25 08:06AM	The 5 Most Interesting Analyst Questions From Viatris's Q1 Earnings Call (StockStory)
07:36AM	Viatris gains China approval for Yupelri to treat COPD (Pharmaceutical Technology)
05:24AM	Viatris presbyopia drug clears second Phase III trial (Clinical Trials Arena)
Jun-26-25 06:55AM	Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia (PR Newswire)
06:00AM	Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA (PR Newswire)
Jun-24-25 04:46AM	Is Viatris Stock Underperforming the S&P 500? (Barchart)
Jun-17-25 12:03AM	3 Reasons to Avoid VTRS and 1 Stock to Buy Instead (StockStory)
Jun-12-25 04:30PM	Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025 (PR Newswire)
Jun-10-25 05:00AM	Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris (Zacks)
Jun-09-25 09:29AM	3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats (Zacks)
07:22AM	VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review (StockStory)
Jun-06-25 02:04PM	Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout (Insider Monkey)
Jun-03-25 11:53AM	TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises (Zacks)
Jun-02-25 08:00AM	Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions (PR Newswire)
May-27-25 06:59AM	Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada (PR Newswire)
May-23-25 05:45AM	Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS (PR Newswire)
May-22-25 06:59AM	Viatris to Participate in Upcoming Investor Conferences (PR Newswire)
May-09-25 12:39PM	Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks)
03:21AM	Viatris Inc (VTRS) Q1 2025 Earnings Call Highlights: Navigating Challenges and Capitalizing on ... (GuruFocus.com)
02:33AM	Q1 2025 Viatris Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-25 03:49PM	Analyst Report: Viatris Inc. (Morningstar Research) +5.70%
12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks)
09:30AM	Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates (Zacks)
08:03AM	Viatris new form of old pain drug scores in large trials (BioPharma Dive)
07:10AM	Viatris: Q1 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook (PR Newswire)
06:45AM	Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO Low Dose Patch for Birth Control in Women of Childbearing Potential (PR Newswire)
06:30AM	Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain (PR Newswire)
May-07-25 12:27PM	Viatris Q1 Earnings Preview: Analysts expect profit to decline by about 27% (Seeking Alpha)
08:15AM	Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates (Zacks)
06:59AM	Viatris Announces Quarterly Dividend (PR Newswire)
May-05-25 04:30PM	Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors (PR Newswire)
09:15AM	Unveiling Viatris (VTRS) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
12:40AM	2 S&P 500 Stocks Worth Investigating and 1 to Avoid (StockStory)
May-02-25 01:20PM	Viatris Q1 Earnings Release: What's in Store for the Stock? (Zacks)
10:00AM	Why The Low Payout Ratio Did Not Stop The Dividend Cut For Organon (Seeking Alpha)
May-01-25 10:01AM	Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 07:42PM	Viatris Inc. (VTRS): Among the Worst Performing Stocks in S&P 500 So Far in 2025 (Insider Monkey)
Apr-29-25 09:56AM	Viatris Inc. (VTRS): One of the Cheap Quarterly Dividend Stocks to Buy Now (Insider Monkey)
Apr-28-25 05:05AM	Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest (StockStory)
Apr-27-25 03:06PM	Viatris Inc. (VTRS): Among Billionaire Ken Fisher's Healthcare Stock Picks with Massive Upside Potential (Insider Monkey)
08:20AM	VTRS SHAREHOLDER REVIEW: Viatris Inc. (NASDAQ:VTRS) was Sued for Fraud after 15% Stock Drop Investors are Urged to Contact BFA Law (GlobeNewswire)
Apr-25-25 09:15AM	Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? (Seeking Alpha)
06:59AM	Viatris to Present at the BofA Securities 2025 Healthcare Conference (PR Newswire)
Apr-24-25 05:01AM	3 Reasons VTRS is Risky and 1 Stock to Buy Instead (StockStory)
Apr-23-25 12:22PM	Is Viatris Inc. (NASDAQ:VTRS) the Best Cheap Stock to Buy Under $10? (Insider Monkey)
Apr-22-25 07:17AM	Viatris files applications in Japan for approval of Effexor to treat GAD (Pharmaceutical Business Review)
Apr-21-25 06:59AM	Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR for the Treatment of Generalized Anxiety Disorder (PR Newswire)
Apr-14-25 09:06AM	Is Viatris Inc. (VTRS) The Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
06:59AM	Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer (PR Newswire)
Apr-11-25 09:55AM	Viatris Inc. (VTRS): Among the High-Dividend Stocks to Invest In Under $10 (Insider Monkey)
Apr-09-25 04:22AM	3 Beaten-Down Stocks That Are Trading Below Their Book Values (Motley Fool) +5.84%
Apr-08-25 09:56AM	Viatris to Pay $335 Million for Settlement of Opioid-Related Claims (Zacks)
Apr-07-25 09:27AM	Viatris to Pay Up to $335 Million in Opioid Settlement (GuruFocus.com)
06:59AM	Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims (PR Newswire)

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Le Goff Corinne	Chief Commercial Officer	Sep 11 '25	Sale	10.25	7,032	72,045	35,299	Sep 12 06:00 PM
Le Goff Corinne	Officer	Sep 11 '25	Proposed Sale	10.25	7,032	72,045		Sep 11 08:05 PM
Smith Scott Andrew	Chief Executive Officer	Aug 12 '25	Buy	9.99	22,000	219,740	314,807	Aug 13 06:08 PM
Smith Scott Andrew	Chief Executive Officer	May 12 '25	Buy	8.94	60,000	536,262	292,807	May 14 06:00 PM
Le Goff Corinne	Chief Commercial Officer	Apr 15 '25	Option Exercise	0.00	41,112	0	60,441	Apr 16 06:00 PM
FINNEY ELISHA W	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	37,832	Mar 05 07:00 PM
Le Goff Corinne	Chief Commercial Officer	Mar 04 '25	Option Exercise	0.00	37,894	0	36,721	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 04 '25	Option Exercise	0.00	207,325	0	328,250	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 03 '25	Option Exercise	0.00	19,348	0	144,590	Mar 05 07:00 PM
Vivaldi Coelho Rogerio	Director	Mar 04 '25	Option Exercise	0.00	21,691	0	21,691	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 04 '25	Option Exercise	0.00	96,431	0	266,825	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 03 '25	Option Exercise	0.00	146,700	0	221,178	Mar 05 07:00 PM
PARRISH MARK W	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	140,395	Mar 05 07:00 PM
Lyons Dillon JoEllen	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	77,691	Mar 05 07:00 PM
KORMAN HARRY	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	113,937	Mar 05 07:00 PM
Groothuis Leo Frans	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	40,350	Mar 05 07:00 PM
HIGGINS MELINA E	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	121,213	Mar 05 07:00 PM
Malik Rajiv	Director	Mar 04 '25	Option Exercise	0.00	892,603	0	1,407,415	Mar 05 07:00 PM
Malik Rajiv	Director	Mar 03 '25	Option Exercise	0.00	89,430	0	587,599	Mar 05 07:00 PM
CORNWELL W DON	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	80,342	Mar 05 07:00 PM
KILTS JAMES M	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	136,422	Mar 05 07:00 PM
MARK RICHARD A	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	91,310	Mar 05 07:00 PM
Roman Brian	Chief Legal Officer	Mar 04 '25	Option Exercise	0.00	206,263	0	265,061	Mar 05 07:00 PM
Roman Brian	Chief Legal Officer	Mar 03 '25	Option Exercise	0.00	18,345	0	84,494	Mar 05 07:00 PM
Mistras Theodora	Chief Financial Officer	Mar 04 '25	Option Exercise	0.00	32,472	0	41,815	Mar 05 07:00 PM
Mistras Theodora	Chief Financial Officer	Jan 01 '25	Option Exercise	0.00	24,065	0	23,084	Jan 03 06:00 PM
Campbell Paul	See Remarks	Nov 11 '24	Sale	12.88	26,925	346,686	126,901	Nov 12 07:00 PM
Campbell Paul	Officer	Nov 11 '24	Proposed Sale	12.88	26,925	346,686		Nov 12 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Viatris Inc

Upgrade your FINVIZ experience